Research statusUnverified identity / no peer-reviewed product-specific evidence
Supplied formUnverified reference-name peptide-related material
Lead time14–21 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Cognitive enhancement, focus, neuroprotection, neuroplasticity, mood support and a six-to-eight-hour duration are marketing or community claims
No product-specific controlled study was found, and evidence about Semax or other peptides cannot establish the effects of an analytically undefined Adamax material.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
114681-65-1
Formula
Confirm supplied form on batch COA
Molecular weight
1032.23-1032.24 Da
Appearance
White to off-white, fluffy lyophilized powder
Purity
≥ 99.0% · target, verify batch COA
Storage
Storage and shipping conditions cannot be standardized until the material's structure, formulation and degradation profile are established. Follow only lot-specific COA and validated stability data, record temperature excursions and do not assign a 14-to-30-day post-reconstitution period without formulation-specific evidence.
MOQ
On request
Lead time
14–21 days
Qualification matrix
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.
Research context
What researchers study about ADMAX
Adamax or ADMAX is a poorly defined gray-market research label commonly described by vendors as an N-terminally acetylated, C-terminally adamantane-modified Semax-related material, sometimes linked in marketing histories to the P21 or "Peptide 021" design. Those structural descriptions have not been independently established. No authoritative PubChem, DrugBank or NCATS/GSRS identity record and no product-specific peer-reviewed human, animal, pharmacokinetic or analytical paper was located in this review. Vendor pages disagree materially on sequence, molecular formula, molecular weight and adamantane attachment, so the label does not currently identify one independently established chemical entity. Community and vendor accounts associate the name with the former research-chemical supplier Ceretropic during approximately 2015-2018 and report that the business closed in 2018, but the claimed inventor and more precise 2016-2017 development timeline were not independently verified. A short English Wikipedia entry created in 2025 repeats a proposed structure and cites the same Medsafe submission described below; it is not independent chemical evidence. Medsafe's June 2025 official submission names Adamax and Semax as examples of ACTH analogues marketed as cognitive enhancers. The official minutes of the 74th Medicines Classification Committee meeting on 23 July 2025 record that the broader peptide-group classification decision was deferred pending additional information; the secretariat later recommended classification, but the minutes do not establish a final legal classification. This regulatory record confirms attention to the product class, not Adamax identity, efficacy or safety. This material is research use only and not for human use.
No product-specific indication is supported
Cognitive, neuroprotective, mood, learning, memory and stroke-recovery claims originate from vendor or community material or extrapolation from Semax; they should be treated as hypotheses requiring independently identified material and controlled research, not ranked as Most Effective, Effective or Moderate.
Mechanism context
The question the literature is testing
No mechanism has been demonstrated for Adamax itself. Statements about adamantane-enhanced lipophilicity, blood-brain-barrier penetration, metabolic stability, BDNF/TrkB signaling, monoamine modulation, ADNP-related microtubule effects, antioxidation or anti-inflammatory activity are structural assumptions or extrapolations from Semax and unrelated compounds. Because the exact Adamax structure has not been independently established, even structure-based mechanistic claims remain provisional.
Evidence map
Research routes and exposure context
Evidence tierAnalytical / laboratory contextResearch areaKhavinson bioregulatorsRoutes reported in sources
SubcutaneousIntranasal
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Safety is unknown because chemical identity, formulation, impurity profile, pharmacokinetics and product-specific toxicology have not been established
This is not an approved medicine and must not be administered to humans
Vendor injection advice, starting doses, cycling, cardiovascular monitoring and pregnancy cautions were removed because they can imply a usable protocol where none exists
Laboratory handling should use a conservative institutional risk assessment for an unverified material
The New Zealand committee's deferred group-level classification discussion does not constitute a safety determination.
Interactions reported in the literature
No product-specific interaction study was located
Claims of similarity or synergy with Semax, P21, BPC-157 or Noopept are community assertions and cannot support compatibility, monitoring rules or combination protocols
An undefined identity also prevents a reliable mechanism-based interaction assessment.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Factory batch documentation
ADMAX factory batch COAs
ADMAX5 mg · WHJLP-ADM5-260514-B
ADMAX10 mg · WHJLP-ADM10-260514-B
Representative records, refreshed periodically
Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.
Independent testing, arranged on request
Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
Help reviewing your COA
Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.
Ask for the current packet, not a generic certificate
A white powder, clear solution or HPLC area percentage cannot establish Adamax identity
Before procurement, require a complete unambiguous structural definition, registry provenance if claimed, synthesis and purification records, high-resolution intact mass, interpretable MS/MS or another orthogonal structure-confirmation method, chromatographic purity with raw chromatograms and impurity profile, quantitative assay or peptide content, counterion and water content where relevant, residual solvents, and lot-specific stability data
Sterility and endotoxin require separate validated tests when claimed
Reject documentation that mixes CAS 114681-65-1, incompatible formulas or masses, or an unspecified adamantane attachment.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
ADMAX-05MG5 mg10 vials
ADMAX-10MG10 mg10 vials
Handling
Storage in the lab and temperature during transit are different decisions
Storage and shipping conditions cannot be standardized until the material's structure, formulation and degradation profile are established. Follow only lot-specific COA and validated stability data, record temperature excursions and do not assign a 14-to-30-day post-reconstitution period without formulation-specific evidence.
State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
Is cold-chain shipping always required?+
Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
No peer-reviewed Adamax-specific study was located in PubMed or PMC. Online claims describing a stroke-recovery observation, BDNF/TrkB upregulation or neurotransmitter modulation could not be traced to primary Adamax publications and must not be represented as clinical or preclinical evidence. Medsafe's June 2025 official submission identifies Adamax and Semax as examples within a proposed ACTH-analogue group, and the official minutes of the 74th Medicines Classification Committee meeting record that the group-level decision was deferred pending additional information. These are the strongest sources located, but they provide regulatory context only and do not verify Adamax chemistry, efficacy, dose or safety. The short Wikipedia entry cites the same Medsafe submission and is not independent evidence. Semax literature may explain why the marketing analogies arose, but it cannot validate an undefined Adamax derivative.
01
Minutes of the 74th Medicines Classification Committee meeting — Peptide Groups
Medsafe, New Zealand Medicines and Medical Devices Safety Authority · 2025 · official regulatory record; group-level context, not evidence of ADMAX identity or efficacy
Medsafe, New Zealand Medicines and Medical Devices Safety Authority · 2025 · official regulatory submission; group-level context, not chemical identity or efficacy evidence
When can an ADMAX reference-name material be appropriate for a study?+
ADMAX is appropriate only when the study question specifically concerns material sold under that reference name and the supplier discloses an exact, testable specification for the offered lot. It is not a substitute for Semax, P21 or another named compound, and those materials are not valid identity references for ADMAX. If the research requires a single well-characterized API, choose a compound with a defined sequence, termini, salt form and authoritative identity record instead.
Why does ADMAX require a stricter order specification than a named API?+
The market name ADMAX is used with conflicting structural descriptions, and no authoritative public identity record fixes one composition. The quotation must therefore state the proposed sequence or complete composition, modifications, termini, counter-ion, molecular-mass basis, formulation and acceptance methods before the buyer approves the order. A trade name, vendor history or comparison with Semax/P21 is not an analytical identity claim.
Related research materials
Compare adjacent molecules and documentation needs.
